Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1905 in Moderate to Severe Atopic Dermatitis
NCT07211542Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1905 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
SHR-1905
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07211542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211542.